Gut Microbiota-Derived Lipopolysaccharides and Short-Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia-Reperfusion Injury

肠道菌群来源的脂多糖和短链脂肪酸通过FFAR2/FFAR3调节肺缺血再灌注损伤中的免疫反应

阅读:2

Abstract

Lung ischemia-reperfusion (IR) injury is a sterile inflammatory process seen in conditions such as hemorrhage-resuscitation and pulmonary embolism. Our previous work suggests that alveolar macrophages (AMs) drive the inflammatory cascade via NLRP3 inflammasome activation, and that gut-derived lipopolysaccharides (LPS) and short-chain fatty acids (SCFAs) influence these responses. However, the precise mechanisms by which gut microbiota signals govern AM function during lung IR remain unclear. Here, we show that germ-free mice exhibit reduced inflammatory responses compared to specific pathogen-free mice following lung IR injury in vivo. In contrast, mice lacking free fatty acid receptor (FFAR)2 or FFAR3-receptors for SCFAs-display heightened inflammation relative to wild-type controls. Ex vivo and in vitro nutritional IR experiments further demonstrate that AMs, primed with LPS, produce IL-1β via NLRP3 inflammasome and caspase-1 activation. Notably, SCFAs significantly diminish IR-induced IL-1β release, indicating a protective effect. These findings support a gut-lung axis in which gut microbiota modulate baseline lung immune capacity or lung immune tone through the transmission of LPS and SCFAs, thereby shaping the lung's response to sterile injury. Gut microbiota-based therapies, including dietary fiber interventions, may thus represent a promising therapeutic strategy for regulating inflammatory processes in the lung.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。